Xoma Halts Development Of Acne Therapy XMP.629, Will Evaluate BPI Program
This article was originally published in The Pink Sheet Daily
Executive Summary
Following disappointing Phase II results, Xoma will not conduct future trials with the bactericidal/permeability-increasing protein derivative XMP.629, its lead candidate. Earlier-stage BPI-derived products are under evaluation.
You may also be interested in...
Xoma’s New Business Strategy Emphasizes Proprietary Pipeline
Antibody developer’s near-term focus is on advancing its anti-inflammatory agent 052 and antimicrobial peptide 629 and partnering Neuprex.
Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116
As Merck’s 21-valent vaccine approaches its 17 June user fee goal, the US CDC’s vaccine committee is looking at new adult age-based recommendations and bracing for a full pipeline led by GSK’s 24-valent candidate.